8-K: TransCode Licenses Oncolytic Immunotherapy for Bladder Cancer

TransCode Therapeutics has secured an exclusive, worldwide license for a preclinical oncolytic immunotherapy platform from Unleash Immuno Oncolytics, Inc., expanding its oncology pipeline.

Summary

• TransCode Therapeutics entered into an Exclusive Licensing Agreement with Unleash Immuno Oncolytics, Inc. on March 2, 2026, acquiring a preclinical candidate program involving genetically-engineered adenoviruses to fight cancer.
• The agreement grants TransCode exclusive, perpetual, irrevocable, worldwide, fully-paid up, royalty-free, sublicensable rights and license to related technology, including drug candidates UIO-524, UIO-525, and UIO-526.
• As consideration, TransCode issued 1,136,364 shares of its newly designated Series C Non-Voting Convertible Preferred Stock to Unleash.
• These Series C Preferred Stock shares represent 6.8% of TransCode's common stock on a fully diluted basis, assuming conversion of all outstanding preferred stock.
• Tungsten Advisors, acting as financial advisor, received 77,841 shares of Series C Preferred Stock as compensation for services rendered.
• The Series C Preferred Stock is not convertible into common stock until TransCode's stockholders approve the conversion in accordance with Nasdaq listing rules, and is subject to a 4.99% beneficial ownership limitation for each holder, which can be adjusted or waived under certain conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive strategic move, expanding the pipeline with a promising, albeit early-stage, asset in a high-unmet-need area. The all-stock nature preserves cash, but the dilution and reliance on stockholder approval introduce some caution.

Positives

• Expansion of the oncology pipeline with an innovative preclinical oncolytic immunotherapy platform, providing an additional 'shot on goal' for cancer treatment.
• Acquisition of exclusive, worldwide, fully paid-up, royalty-free rights to promising drug candidates (UIO-524, UIO-525, UIO-526).
• The lead candidate, UIO-524, targets muscle-invasive bladder cancer (MIBC), an indication with high unmet medical need and a multi-billion dollar global market.
• UIO-524 is designed as a next-generation oncolytic adenovirus engineered for selective replication in malignant cells and cancer-associated stroma, delivering a multi-cytokine immune-activating payload.
• The transaction is structured as an all-stock deal, preserving TransCode's cash reserves.

Negatives

• The issuance of Series C Preferred Stock will result in dilution for existing common stockholders upon conversion, representing 6.8% of the fully diluted common stock.
• Conversion of the Series C Preferred Stock is contingent upon obtaining stockholder approval, introducing a potential delay and uncertainty.
• The acquired drug candidates (UIO-524, UIO-525, UIO-526) are in the preclinical stage, carrying inherent high development risks and a long timeline to potential commercialization.
• Holders of Series C Preferred Stock have specific protective voting rights regarding adverse changes to their preferences or the issuance of further Series C stock.

Risks

• Risks associated with drug discovery and development.
• Risk that clinical trial results will not be consistent with preclinical studies, expectations, or results from previous clinical trials.
• Risks associated with the conduct of clinical trials.
• Risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including its ability to continue as a going concern.
• Risks associated with the timing and outcome of planned regulatory submissions.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks associated with enforcing patents against infringers and defending the patent portfolio against challenges from third parties.
• Risks of competition from other companies developing products for similar uses.
• Risks associated with dependence on third parties.
• Risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions.

Future Outlook

TransCode aims to advance its lead asset, TTX-MC138, into a Phase 2a trial while expanding its pipeline with the innovative preclinical UIO-524 oncolytic immunotherapy candidate. This expansion is intended to address a large and attractive market in aggressive settings like muscle-invasive bladder cancer, providing an additional "shot on goal" for the company.

Management Comments

• "As we are advancing our lead asset, TTX-MC138, into a clinical Phase 2a trial, expanding our pipeline with an innovative preclinical technology such as UIO-524 provides us with an additional shot on goal using a next generation oncolytic immunotherapy candidate intended to address a large and attractive market in more aggressive settings such as MIBC." Dr. Philippe P. Calais, Pharm.D., Ph.D., Chairman and CEO of TransCode.

Industry Context

StockSavvy.ai notes that the acquisition of a preclinical oncolytic immunotherapy platform positions TransCode to capitalize on the growing interest in immuno-oncology and targeted cancer therapies. The focus on muscle-invasive bladder cancer (MIBC) addresses a high-unmet medical need, aligning with broader industry trends towards developing differentiated therapeutic approaches for difficult-to-treat solid tumors. The all-stock transaction structure is common for early-stage asset acquisitions, allowing the company to conserve cash while expanding its pipeline.

Comparison to Industry Standards

• UIO-524 builds on the success of CG Oncology's CG0070, which demonstrated meaningful activity in nonmuscle-invasive bladder cancer (NMIBC). UIO-524 is designed as a next-generation candidate with a structurally related oncolytic adenovirus backbone, incorporating tumorand stroma-targeted replication and a more comprehensive multi-cytokine immune payload, aiming to address more aggressive disease settings like MIBC.
• The 6.8% dilution for an early-stage, preclinical asset acquisition is within the typical range for biotech licensing deals, especially when structured as an all-stock transaction to preserve capital.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution upon conversion of Series C Preferred Stock (6.8% fully diluted). Opportunity for long-term value creation if the new preclinical assets are successful. Requirement to vote on the conversion proposal.
• Unleash Immuno Oncolytics, Inc.: Receives equity in TransCode and gains a partner to advance its preclinical programs.
• Tungsten Advisors: Receives equity compensation for advisory services.

Next Steps

• TransCode expects to file a proxy statement with the SEC regarding the approval of the issuance of Common Stock upon conversion of the Series C Preferred Stock (Unleash Issuance Proposal).
• The company will use commercially reasonable efforts to cause a Form S-3 registration statement for the issued shares to be declared effective by the SEC as soon as practicable.
• Advance TTX-MC138 into a clinical Phase 2a trial.
• Develop the newly licensed UIO-524, UIO-525, and UIO-526 candidates, starting with UIO-524 for muscle-invasive bladder cancer.

Key Dates

Recommendation

The strategic acquisition of a preclinical oncolytic immunotherapy platform is a positive step for pipeline expansion in a high-unmet-need area. However, the early stage of the asset, the contingent nature of the preferred stock conversion, and the inherent risks of drug development, coupled with the dilution for existing shareholders, suggest a 'hold' recommendation. Investors should monitor the progress of the licensed candidates and the outcome of the stockholder approval process.

Keywords

oncolytic immunotherapy, bladder cancer, preclinical, licensing agreement, Series C Preferred Stock, RNAZ, cancer treatment, biotechnology, immuno-oncology, stock dilution